Astria Therapeutics (ATXS) Enterprise Value: 2017-2019
Historic Enterprise Value for Astria Therapeutics (ATXS) over the last 3 years, with Dec 2019 value amounting to $69.7 million.
- Astria Therapeutics' Enterprise Value rose 1168.33% to $69.7 million in Q4 2019 from the same period last year, while for Dec 2019 it was $69.7 million, marking a year-over-year increase of 159.73%. This contributed to the annual value of $504.5 million for FY2024, which is 80.99% up from last year.
- Latest data reveals that Astria Therapeutics reported Enterprise Value of $69.7 million as of Q4 2019, which was up 215.23% from $22.1 million recorded in Q3 2019.
- In the past 5 years, Astria Therapeutics' Enterprise Value ranged from a high of $69.7 million in Q4 2019 and a low of -$22.1 million during Q2 2018.
- Over the past 3 years, Astria Therapeutics' median Enterprise Value value was $20.1 million (recorded in 2017), while the average stood at $20.3 million.
- Data for Astria Therapeutics' Enterprise Value shows a peak YoY increase of 2,381.05% (in 2018) and a maximum YoY decrease of 1,054.53% (in 2018) over the last 5 years.
- Over the past 3 years, Astria Therapeutics' Enterprise Value (Quarterly) stood at $18.0 million in 2017, then plummeted by 136.21% to -$6.5 million in 2018, then soared by 1,168.33% to $69.7 million in 2019.
- Its Enterprise Value stands at $69.7 million for Q4 2019, versus $22.1 million for Q3 2019 and $46.7 million for Q2 2019.